$IKT News

Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Inhibikase Therapeutics Says First Patient Enrolled In Pivotal Phase 3 Study IMPROVE-PAH For Treatment Of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

Inhibikase Therapeutics Files SEC Prospectus To Raise Up To $185M Through Existing ATM Program

Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4

Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company

Reported Earlier, Inhibikase Therapeutics Prices $100M Offering Of 46,091,739 Common Shares At $1.45 And 22,873,779 Pre Funded Warrants At $1.449

Reported Earlier, Inhibikase Therapeutics Prices $100M Offering Of 46,091,739 Common Shares At $1.45 And 22,873,779 Pre Funded Warrants At $1.449

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Inhibikase Therapeutics shares are trading lower after the company announced an offering of common stock and pre-funded warrants.

Inhibikase Therapeutics Announces Common Stock Offering; Terms Not Disclosed

Inhibikase Therapeutics Announces Plans To Advance Its PAH Therapeutic Candidate, IKT-001, Into A Global Phase 3 Trial And Is Expected To Begin In Q1 2026

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Q3 EPS $(0.13), Inline